Loading
Adaptive therapy uses just enough drug to keep a tumour in check, pausing when the burden falls and resuming when it rises, so drug-sensitive cells suppress resistant ones. A prostate cancer pilot with abiraterone lengthened time to progression against historical controls on half the drug; randomised phase 2 trials are the next step.
Adaptive therapy modulates dosing on tumour burden (PSA, imaging or ctDNA), pausing when burden falls below a threshold and resuming when it rises, to maintain a population of sensitive cells that compete with resistant clones. A pilot in metastatic castration-resistant prostate cancer using abiraterone showed prolonged time to progression versus historical controls with roughly half the cumulative drug. The proposal is randomised phase 2 trials in prostate, melanoma and ovarian cancer with pre-specified adaptive algorithms.
Shares Moffitt Cancer Center, Wrong doses, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Ovarian cancer.
Shares TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer, Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Acquired resistance to every therapy.
Shares Moffitt Cancer Center, Acquired resistance to every therapy, Melanoma.
Shares Drug resistance (primary and acquired), Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Acquired resistance to every therapy, Prostate cancer.
Shares Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Acquired resistance to every therapy, Prostate cancer.
Shares Moffitt Cancer Center, Drug resistance (primary and acquired), Prostate cancer.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Melanoma.
Shares Wrong doses, Drug resistance (primary and acquired), Acquired resistance to every therapy.